VIPASANA 100 Tablet is a high-strength formulation of Sertraline, a selective serotonin reuptake inhibitor (SSRI) prescribed for a range of psychiatric conditions including major depressive disorder (MDD), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Each tablet contains 100 mg of Sertraline, a well-established and clinically proven active pharmaceutical ingredient that functions by inhibiting the reuptake of serotonin in the brain, thereby enhancing mood, reducing anxiety, and promoting emotional balance.

Sertraline is known for its favorable efficacy and tolerability profile and is often recommended for long-term management of depressive and anxiety-related conditions. VIPASANA 100 acts gradually, with noticeable improvements often appearing within two to four weeks of consistent use. It is typically taken once daily, with or without food, and its dosage may be adjusted by a healthcare provider depending on individual response and tolerability. As with most SSRIs, abrupt discontinuation should be avoided, and tapering is recommended when stopping treatment.

Manufactured in a state-of-the-art WHO-GMP-certified facility, VIPASANA 100 Tablet is produced with strict adherence to international quality standards, ensuring pharmaceutical-grade purity, stability, and bioavailability. The tablet is designed for consistent absorption and sustained therapeutic effect, making it a reliable treatment option for both acute and chronic phases of mental health management. The product is suitable for private labeling, contract manufacturing, and global distribution, and can be tailored to meet the regulatory and packaging requirements of various markets.

VIPASANA 100 is generally well-tolerated, though patients may experience temporary side effects such as nausea, headache, insomnia, dry mouth, dizziness, or gastrointestinal discomfort. In rare cases, more serious effects such as serotonin syndrome, suicidal thoughts, or manic episodes may occur, particularly at the start of treatment or after dose escalation. Therefore, patient monitoring is essential, especially in young adults and those with a history of bipolar disorder or substance use.

This medication should not be used in combination with monoamine oxidase inhibitors (MAOIs) or other serotonergic agents without proper medical oversight due to the risk of serotonin toxicity. Caution is advised in individuals with liver dysfunction, epilepsy, or seizure disorders. Pregnant or breastfeeding women should use VIPASANA 100 only under strict medical supervision when the potential benefits outweigh the risks.

The branding of VIPASANA reflects a commitment to mental clarity and emotional healing, aligning with the therapeutic objectives of Sertraline-based treatment. It serves as a dependable option in psychiatric care, trusted by physicians and patients alike. Whether used as part of an initial therapeutic plan or in maintenance therapy, VIPASANA 100 offers a clinically validated, high-quality solution for addressing mood and anxiety disorders with consistency and efficacy.

VIPASANA 100 is packaged securely and labeled according to global compliance norms, ensuring shelf stability, batch traceability, and patient safety. Its availability through third-party manufacturing and distribution models makes it a strategic addition to any pharmaceutical portfolio seeking to meet the rising demand for high-quality psychiatric medications. Its clinical performance, coupled with dependable manufacturing, makes VIPASANA 100 a product of choice for healthcare providers aiming to deliver long-term mental health support with confidence.